Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New compounds effective against Alzheimer’s disease onset and progression

09.11.2004


Drug discovery researchers at Northwestern University have developed a new class of compounds that have the potential to reduce the inflammation of brain cells and the neuron loss associated with Alzheimer’s disease.



The new class of compounds are aminopyridazines. The original compound, called MW01-070C, is used in an injectable form. More recently developed compounds, such as MW01-2-151WH and MW01-5-188WH, can be taken by mouth.

The compounds were designed and synthesized in the laboratory of D. Martin Watterson, J. G. Searle Professor of Molecular Biology and Biochemistry and professor of molecular pharmacology and biological chemistry, Northwestern University Feinberg School of Medicine, using a synthetic chemistry platform developed by the Northwestern Drug Discovery Program for the rapid discovery of new potential therapeutic targets.


The aminopyridazines are targeted for the potential treatment of certain neurodegenerative diseases that are characterized by neuroinflammation and neuronal loss, such as Alzheimer’s disease, Parkinson’s disease, stroke and traumatic brain injury. The compounds inhibit over-activation of glia, important cells of the central nervous system that normally help the body mount a response to injury or developmental change but are overactivated in certain neurodegenerative diseases.

The efficacy and safety of the compounds in an Alzheimer’s disease animal model was evaluated in collaboration with Linda J. Van Eldik, professor of cell and molecular biology at Feinberg.

The scientists described their Alzheimer’s disease drug discovery efforts in recent issues of the Journal of Molecular Neuroscience and the journal Neurobiology of Aging, and a publication that will appear in early 2005 in the journal Current Alzheimer Research. The studies have important implications for future drug development because they provide a proof of concept that targeting neuroinflammation with aminopyridazines is a viable Alzheimer’s disease drug discovery approach that has the potential to modulate disease onset and progression, Van Eldik said.

Deposition of the beta-amyloid plaques and neurofibrillary tangles of Alzheimer’s disease is associated with glial activation, loss of neurons and decline of cognitive function. Long-term or excessive activation of glia increases production of chemokines and cytokines, such as interleukin-1 beta (IL-1b), and oxidative stress-related enzymes, such as a highly active form of nitric oxide synthase (iNOS). The excessive production of the inflammation-related substances can, in turn, contribute to further exacerbation of the disease process.

IL-1b is involved in glial inflammatory and neuronal dysfunction responses, and variants of the IL-1 gene are associated with increased risk for Alzheimer’s disease. The iNOS induced as a result of glial activation generates nitric oxide (NO), which can exist in toxic forms that damage neurons. Therefore, development of new compounds that can modulate these disease-linked biological processes may represent alternative therapeutic approaches and lead to future identification of new drug discovery targets, Van Eldik said.

Van Eldik and co-researchers found that the aminopyridazines inhibited both oxidative and inflammatory cytokine pathways and reduced human amyloid beta (Ab)-induced glial activation in a mouse specially designed to develop many of the hallmarks of Alzheimer’s disease pathology, including neuroinflammation, neuronal and synaptic degeneration and amyloid disposition, often called plaques.

Inhibition of neuroinflammation correlated with a decreased neuron loss, restoration towards control levels of synaptic dysfunction biomarkers in the hippocampus and diminished amyloid plaque deposition. Consistent with the pathology changes, treatment with the aminopyridazines also attenuated behavioral deficits in the mice that are due to injury in the part of the brain called the hippocampus, a region that is gradually destroyed in neurodegenerative diseases such as Alzheimer’s. The Northwestern investigators are now seeking to raise the funding necessary for testing in humans.

Collaborating with Watterson and Van Eldik on this research were Jeffrey M. Craft, a medical scientist predoctoral student in the Drug Discovery Training Program, and Wenhui Hu and Hantamalala Ranay Ranaivo, postdoctoral scholars in the Drug Discovery Training Program.

Elizabeth Crown | EurekAlert!
Further information:
http://www.northwestern.edu

More articles from Life Sciences:

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

nachricht Toward a 'smart' patch that automatically delivers insulin when needed
18.01.2017 | American Chemical Society

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

The Great Unknown: Risk-Taking Behavior in Adolescents

19.01.2017 | Studies and Analyses

Magnetic moment of a single antiproton determined with greatest precision ever

19.01.2017 | Physics and Astronomy

CRISPR meets single-cell sequencing in new screening method

19.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>